SAN ANTONIO, Aug. 3, 2026 /PRNewswire/ — Cizzle Bio, Inc., a biotechnology company advancing biomarker blood tests for early cancer detection, today announced that it
New research explores the growing evidence behind whole blood transfusions—and how South Texas Blood & Tissue helped shape this lifesaving approach. Whole blood is making
SAN ANTONIO, Texas — BBG Advanced Therapies, a subsidiary of nonprofit BioBridge Global, today announced a collaboration with Kite, a Gilead Company and global leader
SAN ANTONIO, Texas — BBG Advanced Therapies (BBG AT), a subsidiary of San Antonio based nonprofit BioBridge Global (BBG), has entered into a collaboration with
International delegation explores San Antonio’s growing leadership in biomedical innovation and advanced therapies. BioBridge Global recently welcomed a delegation of approximately 30 ambassadors and consular
Cell and gene therapies (CGTs) are opening new possibilities for patients with cancer, rare diseases, blood disorders, and autoimmune conditions. As these groundbreaking therapies move
Technology in Biomanufacturing Cleanrooms Cleanroom technology continues to evolve as industries face stricter regulatory requirements, higher product quality expectations, and increasing pressure to reduce contamination
BBG Advanced Therapies Subsidiary of BioBridge Global is advancing our role as an integrated partner for advanced therapy development by delivering cGMP-compliant umbilical cord tissue
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
In a recent webinar, Future Proofing Cell & Gene Therapy: Strategies to Secure Your Leukapheresis Supply Chain, Heather Munoz, Principal of Global Market Development, and James
South Texas Blood & Tissue COO recognized for exceptional leadership and contributions to donor services and transfusion medicine. Audra Taylor, Chief Operating Officer of South
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally